Corporate ActionApr 27, 2026, 04:53 PM
MOBI Files S-1/A for Initial Public Offering
AI Summary
Mobia Medical, Inc. (MOBI) filed an S-1/A for its initial public offering of common stock, which is expected to trade on the Nasdaq Global Select Market. The company, a commercial-stage medical device firm, offers the FDA-approved Vivistim Paired VNS System for chronic ischemic stroke recovery. Mobia reported significant growth, with 2025 revenue of $32.0 million, a 104.8% increase year-over-year, and over 1,000 Vivistim System implants to date. The company also recently issued $40.0 million in convertible notes that will convert at the IPO.
Key Highlights
- Mobia Medical, Inc. filed S-1/A for its initial public offering of common stock.
- Expected to trade on Nasdaq Global Select Market under the symbol "MOBI".
- 2025 revenue increased 104.8% to $32.0 million from $15.6 million in 2024.
- Gross margin was 81.1% in 2025, up from 79.6% in 2024.
- Net loss was $46.5 million in 2025, compared to $24.6 million in 2024.
- Over 1,000 Vivistim System implants performed, with approximately 700 in 2025.
- Issued $40.0 million in 2026 Convertible Notes, converting into common stock at IPO.
- Vivistim System is FDA-approved and granted breakthrough device status in 2021.